Accepted Manuscript

Title: Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility

Authors: Lilia A. Rabia, Alec A. Desai, Harkamal S. Jhajj,

Peter M. Tessier


PII: S1369-703X(18)30184-0

DOI: https://doi.org/10.1016/j.bej.2018.06.003

Reference: BEJ 6967

To appear in: Biochemical Engineering Journal

Received date: 3-3-2018 Revised date: 2-6-2018 Accepted date: 4-6-2018



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility

Lilia A. Rabia¹, Alec A. Desai², Harkamal S. Jhajj³ and Peter M. Tessier^{1,2,3,4*}

- 1. Center for Biotechnology & Interdisciplinary Studies, Isermann Dept. of Chemical & Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180
- 2. Departments of Chemical Engineering, 3. Biomedical Engineering, 4. Pharmaceutical Sciences, Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.

Keywords: mAb, Fab, Fc, CDR, aggregation, developability

*Correspondence: ptessier@umich.edu

Highlights

- Antibodies display trade-offs between key properties during affinity maturation
- Antibody mutations that increase affinity are commonly destabilizing
- Affinity-enhancing mutations can reduce antibody specificity and solubility
- New methods are reported for minimizing trade-offs between key antibody properties

The widespread use of monoclonal antibodies for therapeutic applications has led to intense interest in optimizing several of their natural properties (affinity, specificity, stability, solubility and effector functions) as well as introducing non-natural activities (bispecificity and cytotoxicity mediated by conjugated drugs). A common challenge during antibody optimization is that improvements in one property (e.g., affinity) can lead to deficits in other properties (e.g., stability). Here we review recent advances in understanding trade-offs between different antibody properties, including affinity, specificity, stability and solubility. We also review new approaches for co-optimizing multiple antibody properties and discuss how these methods can be used to rapidly and systematically generate antibodies for a wide range of applications.

1. Introduction

Monoclonal antibodies (mAbs) are being used in diverse therapeutic and diagnostic applications due to several of their attractive properties (Fig. 1) [1-3]. The most important antibody properties relate to their natural functions, such as their high binding affinity and specificity mediated by their complementarity-determining regions (CDRs) within the variable regions (variable heavy, V_H, and variable light, V_L). Other key natural antibody properties include their effector functions – such as antibody-dependent cell-mediated cytotoxicity

Download English Version:

https://daneshyari.com/en/article/6483880

Download Persian Version:

https://daneshyari.com/article/6483880

<u>Daneshyari.com</u>